The ultimate goal in TB treatment is the development of drug combinations to effectively, safely and quickly treat all forms of TB. In order for these new combinations to be developed it is vital that there is a healthy TB drug pipeline with a number of compounds in all phases of development, which is not the case currently. The market for TB regimens is not lucrative and TB R&D is chronically underfunded which translates into slow or stalled scientific progress. A range of stakeholders will examine the current system and look for ways to improve the drug and regimen pipeline.

Target audience
Researchers in early and late phase drug development, researchers in new regimen development, pharmaceutical companies and funders of drug development.

Objectives
1. Outline the current barriers and issues with TB R&D in TB drug and regimen development
2. Examine weaknesses at various stages of the TB drug pipeline
3. Outline funding trends and gaps
4. Discuss potential novel mechanisms to stimulate a healthier drug pipeline

Keywords
New drugs; TB research and development; new regimens; drug development; clinical trials

Coordinator(s)
Grania Brigden (France)

Chair(s)
Christian Lienhardt (Switzerland)

Presentations
14:30 - 14:45 Barriers in early drug development
Stewart Cole (Switzerland)

14:50 - 15:05 Eli Lilly perspective on issues with TB drug and regimen development
Evan Lee (Switzerland)

15:10 - 15:25 Barriers for combination trials
Robert Horsburgh (USA)

15:30 - 15:45 Existing funding mechanisms for TB R&D
Colleen Daniels (USA)

15:50 - 16:05 A novel solution to the current R&D problem
Manica Balasegaram (Switzerland)

16:10 - 16:30 Discussion